These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23695774)

  • 1. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials.
    Roubille F; Prunier F; Barrère-Lemaire S; Leclercq F; Piot C; Kritikou EA; Rhéaume E; Busseuil D; Tardif JC
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):315-31. PubMed ID: 23695774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of erythropoietin for conferring cardioprotection complementing reperfusion.
    Binbrek AS; Mittal B; Rao KN; Sobel BE
    Coron Artery Dis; 2007 Nov; 18(7):583-5. PubMed ID: 17925614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of erythropoietin on myocardial infarction in rats: the role of AMP-activated protein kinase signaling pathway.
    Li XJ; Wang XW; Du YJ
    Am J Med Sci; 2011 Aug; 342(2):153-9. PubMed ID: 21415704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin in cardiac disease: effective or harmful?
    Mastromarino V; Musumeci MB; Conti E; Tocci G; Volpe M
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14(12):870-8. PubMed ID: 23811836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
    Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside.
    Lipsic E; Schoemaker RG; van der Meer P; Voors AA; van Veldhuisen DJ; van Gilst WH
    J Am Coll Cardiol; 2006 Dec; 48(11):2161-7. PubMed ID: 17161240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.
    Gäbel R; Klopsch C; Furlani D; Yerebakan C; Li W; Ugurlucan M; Ma N; Steinhoff G
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):20-5; discussion 25. PubMed ID: 19380336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target.
    Kagaya Y; Asaumi Y; Wang W; Takeda M; Nakano M; Satoh K; Fukumoto Y; Shimokawa H
    Tohoku J Exp Med; 2012 Jun; 227(2):83-91. PubMed ID: 22688525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin and the heart: physiological effects and the therapeutic perspective.
    Sanchis-Gomar F; Garcia-Gimenez JL; Pareja-Galeano H; Romagnoli M; Perez-Quilis C; Lippi G
    Int J Cardiol; 2014 Feb; 171(2):116-25. PubMed ID: 24377712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study.
    Ferrario M; Arbustini E; Massa M; Rosti V; Marziliano N; Raineri C; Campanelli R; Bertoletti A; De Ferrari GM; Klersy C; Angoli L; Bramucci E; Marinoni B; Ferlini M; Moretti E; Raisaro A; Repetto A; Schwartz PJ; Tavazzi L
    Int J Cardiol; 2011 Feb; 147(1):124-31. PubMed ID: 19906454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with erythropoietin and granulocyte colony-stimulating factor enhances neovascularization and improves cardiac function after myocardial infarction.
    Xue J; Du G; Shi J; Li Y; Yasutake M; Liu L; Li J; Kong Y; Wang S; Yun F; Li W
    Chin Med J (Engl); 2014; 127(9):1677-83. PubMed ID: 24791874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis stimulation in acute ischemic syndromes.
    Ruifrok WP; Lipsic E; de Boer RA; van Gilst WH; van Veldhuisen DJ
    Heart Fail Clin; 2010 Jul; 6(3):313-21. PubMed ID: 20630406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [⁶⁸Ga]Annexin A5 and [¹⁸F]FDG PET.
    Todica A; Zacherl MJ; Wang H; Böning G; Jansen NL; Wängler C; Bartenstein P; Kreissl MC; Hacker M; Brunner S; Lehner S
    J Nucl Cardiol; 2014 Dec; 21(6):1191-9. PubMed ID: 25189144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction.
    Olea FD; De Lorenzi A; Cortés C; Cuniberti L; Fazzi L; Flamenco Mdel P; Locatelli P; Cabeza Meckert P; Bercovich A; Laguens R; Crottogini A
    Int J Cardiol; 2013 May; 165(2):291-8. PubMed ID: 21944383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin: new horizon in cardiovascular medicine.
    Koul D; Dhar S; Chen-Scarabelli C; Guglin M; Scarabelli TM
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):5-12. PubMed ID: 18221097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis.
    Brunner S; Winogradow J; Huber BC; Zaruba MM; Fischer R; David R; Assmann G; Herbach N; Wanke R; Mueller-Hoecker J; Franz WM
    FASEB J; 2009 Feb; 23(2):351-61. PubMed ID: 18827024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury.
    Shan X; Xu X; Cao B; Wang Y; Guo L; Zhu Q; Li J; Que L; Chen Q; Ha T; Li C; Li Y
    Int J Cardiol; 2009 May; 134(3):384-92. PubMed ID: 18672303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of erythropoietin combined with granulocyte-colony stimulating factor in the treatment of acute myocardial infarction in rats].
    Fu ZH; Dong W; Gai LY; Wang F; Ding R; Chen YD
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan; 31(1):17-22. PubMed ID: 21269949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling.
    Miki T; Miura T; Yano T; Takahashi A; Sakamoto J; Tanno M; Kobayashi H; Ikeda Y; Nishihara M; Naitoh K; Ohori K; Shimamoto K
    J Pharmacol Exp Ther; 2006 Apr; 317(1):68-75. PubMed ID: 16377761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
    van der Meer P; Lipsic E; Henning RH; Boddeus K; van der Velden J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    J Am Coll Cardiol; 2005 Jul; 46(1):125-33. PubMed ID: 15992646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.